H3 influenza a virus

Patent metadata

Field	Value
Publication number	US-9492530-B2
Application number	US-201514840759-A
Country	US
Kind code	B2
Filing date	Aug 31, 2015
Priority date	Jan 11, 2005
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

First claim

What is claimed is:

1. A method of preparing a vaccine, comprising
providing an isolated live H3 influenza virus comprising a gene segment with sequences for a HA having SEQ ID NO: 1 or a HA having at least 98% amino acid sequence identity to SEQ ID NO:1 which HA does not have a valine at position 78 or an asparagine at position 159;
combining the isolated H3 influenza virus with an adjuvant or treating the isolated H3 influenza virus with an agent that inactivates the virus, thereby providing a composition; and
providing an individual dose of the composition comprising an amount effective to immunize a mammal.

2. The method of claim 1 wherein the mammal is a horse.

3. The method of claim 1 wherein the mammal is a canine.

4. The method of claim 1 wherein the composition comprises inactivated virus.

5. The method of claim 1 wherein the H3 influenza virus comprises at least one of the following gene segments: a gene segment with sequences for a NA having SEQ ID NO:2 or having at least 95% amino acid sequence identity to SEQ ID NO:2, a gene segment with sequences for a PB1 having SEQ ID NO:3 or having at least 95% amino acid sequence identity to SEQ ID NO:3, a gene segment with sequences for a PB2 having SEQ ID NO:4 or having at least 95% amino acid sequence identity to SEQ ID NO:4, a gene segment with sequences for a PA having SEQ ID NO:5 or having at least 95% amino acid sequence identity to SEQ ID NO:5, a gene segment with sequences for a NP having SEQ ID NO:6 or having at least 95% amino acid sequence identity to SEQ ID NO:6, a gene segment with sequences for a M1 having SEQ ID NO:7 or having at least 95% amino acid sequence identity to SEQ ID NO:7, a gene segment with sequences for a M2 having SEQ ID NO:17 or having at least 95% amino acid sequence identity to SEQ ID NO: 17, a gene segment with sequences for a NS1 having SEQ ID NO:8 or having at least 95% amino acid sequence identity to SEQ ID NO:8, or a gene segment with sequences for a NS2 having SEQ ID NO: 18 or having at least 95% amino acid sequence identity to SEQ ID NO: 18.

6. The method of claim 1 wherein the composition further comprises a different isolated influenza virus.

7. The method of claim 1 wherein the composition further comprises a pathogen other than the H3 influenza virus.

8. The method of claim 1 wherein the composition comprises the adjuvant.

9. The method of claim 1 further comprises a pharmaceutically acceptable carrier.

10. The method of claim 9 wherein the carrier is suitable for intramuscular administration.

11. The method of claim 1 wherein the composition is freeze-dried.

12. A method of preparing a vaccine, comprising
providing an isolated live H3 influenza virus comprising a gene segment with sequences for a HA having SEQ ID NO: 1 or a HA having at least 95% amino acid sequence identity to SEQ ID NO:1 which HA has an alanine at position 78 and a serine at position 159;
combining the isolated H3 influenza virus with an adjuvant or treating the isolated H3 influenza virus with an agent that inactivates the virus, thereby providing a composition; and
providing an individual dose of the composition comprising an amount effective to immunize a mammal.

13. The method of claim 12 wherein the mammal is a horse.

14. The method of claim 12 wherein the mammal is a canine.

15. The method of claim 12 wherein the composition comprises inactivated virus.

16. The method of claim 12 wherein the carrier is suitable for intranasal administration.

17. The method of claim 12 wherein the composition further comprises a different isolated influenza virus.

18. The method of claim 12 wherein the composition further comprises a pathogen other than the H3 influenza virus.

19. The method of claim 12 wherein the composition comprises the adjuvant.

20. The method of claim 12 further comprising a pharmaceutically acceptable carrier suitable for intramuscular or intranasal administration.

Assignees

• Wisconsin Alumni Res Found (Warf)
• Wisconsin Alumni Res Found

Inventors

• Olsen Christopher W
• Landolt Gabriele A
• Karasin Alexander I

Classifications

• A61K2039/5254

  avirulent or attenuated · CPC title

• G01N33/56983

  Viruses · CPC title

• C07K14/005

  from viruses · CPC title

• A61K39/145 Primary

  Orthomyxoviridae, e.g. influenza virus · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title